New drug shows promise in taming rare, severe blood vessel disease

NCT ID NCT04157348

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 30 times

Summary

This study tests a new drug, benralizumab, against an existing one, mepolizumab, for people with a rare disease called EGPA that causes inflammation in blood vessels. About 140 adults with active disease despite standard care will receive either drug for a year, with the goal of achieving remission (no symptoms) while reducing steroid use. The study is in its final phase and aims to see if benralizumab works better or is safer than the current treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Denver, Colorado, 80206, United States
Research Site

Ann Arbor, Michigan, 48109, United States
Research Site

Rochester, Minnesota, 55905-0001, United States
Research Site

Albuquerque, New Mexico, 87106, United States
Research Site

Great Neck, New York, 11021, United States
Research Site

New York, New York, 10021, United States
Research Site

Philadelphia, Pennsylvania, 19104, United States
Research Site

Denison, Texas, 75020, United States
Research Site

Seattle, Washington, 98115, United States
Research Site

Brussels, 1070, Belgium
Research Site

Brussels, 1090, Belgium
Research Site

Calgary, Alberta, T2N 4Z6, Canada
Research Site

Hamilton, Ontario, L8N 4A6, Canada
Research Site

Toronto, Ontario, M5G 1E2, Canada
Research Site

Toronto, Ontario, M5T 3A9, Canada
Research Site

Dijon, 21079, France
Research Site

Marseille, 13915, France
Research Site

Montpellier, 34090, France
Research Site

Nantes, 44093, France
Research Site

Paris, 75014, France
Research Site

Paris, 75877, France
Research Site

Suresnes, 92151, France
Research Site

Toulouse, 31059, France
Research Site

Bamberg, 96049, Germany
Research Site

Freiburg im Breisgau, 79106, Germany
Research Site

Hamburg, 20251, Germany
Research Site

Kirchheim, 73230, Germany
Research Site

Lübeck, 23538, Germany
Research Site

Ashkelon, 7830604, Israel
Research Site

Beersheba, 84101, Israel
Research Site

Jerusalem, 91120, Israel
Research Site

Ramat Gan, 52621, Israel
Research Site

Rehovot, 7661041, Israel
Research Site

Tel Aviv, 6423906, Israel
Research Site

Cuneo, 12100, Italy
Research Site

Florence, 50141, Italy
Research Site

Milan, 20132, Italy
Research Site

Milan, 20162, Italy
Research Site

Naples, 80131, Italy
Research Site

Roma, 00168, Italy
Research Site

Torino, 10128, Italy
Research Site

Chiba, 260-0877, Japan
Research Site

Kita-gun, 761-0793, Japan
Research Site

Sagamihara-shi, 228-0815, Japan
Research Site

Sendai, 980-8574, Japan
Research Site

Shinjuku-ku, 162-8666, Japan
Research Site

Cambridge, CB2 0QQ, United Kingdom
Research Site

Leicester, LE3 9QP, United Kingdom
Research Site

London, SE19RT, United Kingdom
Research Site

Portsmouth, PO6 3LY, United Kingdom

Conditions

Explore the condition pages connected to this study.

EOSINOPHILIC GRANULOMATOUS VASCULITIS